ophthalmologytimes5 分钟
FDA grants fast track status to FELIQS’ FLQ-101 for ROP
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
All the News That’s Fit: Lively livers, picky eaters and stretchy skin
Metabolic dysfunction-associated steatohepatitis, or MASH, is a kind of chronic liver inflammation and scarring caused by ...